Lung Cancer News and Research

Latest Lung Cancer News and Research

Activating rearrangements in receptor genes are more common than previously thought

A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,--an MSKCC surgeon, researcher and the Director of the Brain Tumor Center--and was published in the October 1 issue of the journal Genes & Development.

1 Oct 2010

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

A study led by researchers at the University of California, San Diego shows that California's 40 year-long tobacco control program has resulted in lung cancer rates that are nearly 25 percent lower than other states.

1 Oct 2010

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

1 Oct 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

Study shows tobacco control program reduces lung cancer rate

30 Sep 2010

MicroRNAs assay may allow better targeted therapy for lung cancer patients

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

30 Sep 2010

AACR to host Third Conference on The Science of Cancer Health Disparities

The American Association for Cancer Research will host its Third Conference on The Science of Cancer Health Disparities at the Loews Hotel in Miami from Sept. 30 to Oct. 3, 2010.

29 Sep 2010

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

29 Sep 2010

Circulating tumor cells may be promising alternative for tumor biopsies

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

Researchers identify biomarker to predict tivozanib drug resistance

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

29 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.

29 Sep 2010

IsoRay reports increase revenue for 2010 fiscal year

IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.

28 Sep 2010

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.

28 Sep 2010

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a randomized, controlled, investigator sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.

27 Sep 2010

Concerted effort yields significant progress in reducing depression, HIV/AIDS, and osteoporosis in women

A concerted effort to boost research on women's health over the last two decades has lessened the burden of disease and reduced deaths among women due to cardiovascular disease, breast cancer, and cervical cancer, says a new report from the Institute of Medicine. The effort has yielded less but still significant progress in reducing the effects of depression, HIV/AIDS, and osteoporosis on women, added the committee that wrote the report.

24 Sep 2010

NCCN launches series of guidelines on cancer treatment

Patients with cancer and their caregivers have a new resource to help them navigate the maze of treatment options that they often confront. Today at the NCCN Patient Advocacy Summit in Washington D.C., the National Comprehensive Cancer Network launched its new series of NCCN Guidelines for Patients, consumer-friendly translations of the NCCN Clinical Practice Guidelines in Oncology outlining appropriate cancer treatment.

24 Sep 2010

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG in pancreatic cancer, the company announced today.

24 Sep 2010

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that the National Cancer Institute has purchased Caliper's Quantum FX, a stand-alone microCT system for pre-clinical imaging, to study spontaneous tumor models in lung cancer.

23 Sep 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Activating rearrangements in receptor genes are more common than previously thought

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

Study shows tobacco control program reduces lung cancer rate

MicroRNAs assay may allow better targeted therapy for lung cancer patients

AACR to host Third Conference on The Science of Cancer Health Disparities

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

Circulating tumor cells may be promising alternative for tumor biopsies

Researchers identify biomarker to predict tivozanib drug resistance

Researchers discover new diagnostic test for prostate cancer

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

IsoRay reports increase revenue for 2010 fiscal year

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

Concerted effort yields significant progress in reducing depression, HIV/AIDS, and osteoporosis in women

NCCN launches series of guidelines on cancer treatment

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

The ultimate guide to lung research tools and protocols eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in